Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 15 568 M
EBIT 2017 7 668 M
Net income 2017 -
Debt 2017 18 703 M
Yield 2017 1,13%
Sales 2018 16 505 M
EBIT 2018 8 230 M
Net income 2018 656 M
Debt 2018 15 869 M
Yield 2018 0,98%
P/E ratio 2017 -
P/E ratio 2018 561,05
EV / Sales2017 7,15x
EV / Sales2018 6,58x
Capitalization 92 656 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi,... 
Sector
Pharmaceuticals
Calendar
02/24Ex-dividend day
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
02/21 Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/13 Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
02/13 Stada to hold takeover talks with rival suitors Cinven and Advent
02/13DJALLERGAN : to Buy Fat Treatment Maker Zeltiq for $2.3 Billion
02/08 Allergan says U.S. tax reform unlikely in 2017, sees strong year
02/08DJALLERGAN : Results Boosted by New, Established Drugs -- Update
02/08DJALLERGAN : Results Boosted by New, Established Drugs
01/24 U.S. reaches settlement with Endo on pay-for-delay charges
01/18DJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
More news
Sector news : Pharmaceuticals - NEC
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 267 $
Spread / Average Target 8,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC92 656
JOHNSON & JOHNSON3.74%331 089
ROCHE HOLDING LTD.5.98%209 906
PFIZER INC.3.42%206 688
NOVARTIS AG3.51%201 806
MERCK & CO., INC.10.91%181 558
More Results